Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/11/2019
SIETES contiene 92833 citas

 
 
 1 a 6 de 6 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Lau WCY, Chan EW, Cheung C-L, Sing CW, Man KK, Lip GY, Siu CW, Lam JK, Lee AC, Wong IC. Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation. JAMA 2017;317:1151-8. [Ref.ID 101498]
2. Cita con resumen
Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation 2016;133:1540-7. [Ref.ID 100280]
3.Tiene citas relacionadas Cita con resumen
Lip GY, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015;65:1385-94. [Ref.ID 99047]
4.Tiene citas relacionadas Cita con resumen
Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chen SA. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?. J Am Coll Cardiol 2015;65:635-42. [Ref.ID 99046]
5.Tiene citas relacionadas Cita con resumen
Lane DA, Lip GY. Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk. Lancet Neurol 2010;9:1157-63. [Ref.ID 90083]
6.Tiene citas relacionadas
Chung NA, Lip GY, Beevers M, Beevers DG. Angiotensin-II-receptor inhibitors in pregnancy. Lancet 2001;357:1620-1. [Ref.ID 56771]
Seleccionar todas
 
 1 a 6 de 6